BOT
BOTANIX PHARMA LTD ORDINARYBotanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older. It also develops BTX 1503, a transdermal gel formulation, which is in Phase 3 clinical trial for the treatment of serious acne in adults and teenagers; BTX 1702 that is in Phase 1b/2 clinical trial to treat papulopustular rosacea; BTX 1204A for treating atopic dermatitis; and BTX 1801, which has been completed Phase 2a clinical trial for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus. The company was incorporated in 1984 and is based in Melbourne, Australia.
BOT
BOT
BOTANIX PHARMA LTD ORDINARY
Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older.
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 28 Aug | — | — |
| 27 Aug | — | — |
| 26 Aug | — | — |
| 25 Aug | 0.62% | — |
| 24 Aug | 0.62% | — |
| 21 Aug | 0.60% | — |
| 20 Aug | 0.58% | — |
| 19 Aug | 0.58% | — |
| 18 Aug | 0.58% | — |
| 17 Aug | 0.58% | — |
| 14 Aug | 0.59% | — |
| 13 Aug | 0.59% | — |
Botanix Pharma LTD (BOT) Short Interest Summary
Botanix Pharma LTD (BOT) currently has 0.62% of its shares sold short (17.1 million shares, worth approximately $359K), based on ASIC short position data reported on 25 August 2026 (T+4 reporting lag). That makes BOT the #287 most shorted stock on the ASX most shorted list. Short interest in BOT is up 0.04% over the past week and up 0.04% over the past month. BOT is part of the Health Care sector on the ASX.
Recent BOT Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 25 Aug 2026 | 0.62% | 17.1M | $0.02 |
| 24 Aug 2026 | 0.62% | 17.0M | $0.02 |
| 21 Aug 2026 | 0.60% | 16.3M | $0.02 |
| 20 Aug 2026 | 0.58% | 16.0M | $0.02 |
| 19 Aug 2026 | 0.58% | 16.0M | $0.02 |
| 18 Aug 2026 | 0.58% | 16.0M | $0.02 |
| 17 Aug 2026 | 0.58% | 16.0M | $0.02 |
| 14 Aug 2026 | 0.59% | 16.1M | $0.02 |
| 13 Aug 2026 | 0.59% | 16.1M | $0.02 |
| 12 Aug 2026 | 0.58% | 15.9M | $0.02 |
BOT Short Selling — Frequently Asked Questions
What is Botanix Pharma LTD (BOT)'s current short interest?
Botanix Pharma LTD (BOT) currently has a short interest of 0.62% of total shares outstanding. This means 0.62% of BOT's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is BOT heavily shorted on the ASX?
BOT has a relatively low short interest of 0.62%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for BOT investors?
Short interest in BOT shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.62%, BOT's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this BOT short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for BOT.